🔗 Share this article

Elected officials have expressed alarm that the United Kingdom's negotiated accords with Washington are "fundamentally unstable." This follows revelations that a much-touted deal on pharmaceutical tariffs, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond vague headline terms outlined by government press releases.

A Deal Without Detail

The arrangement concerning medicines, promoted as a "significant" achievement, exists as an "agreement in principle" without a signed legal text. Critics have noted that the official announcements from the UK and US governments frame the deal in divergent terms. The British version focuses on securing "duty-free access" as a unique achievement, while the American announcement dwells on the expectation for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has promised concessions to increase medicine costs in return for nothing more than a pledge from President Trump," stated David Henig, a trade expert. "We know he has form for not honouring his word."

Wider Concerns Amidst a Suspended Agreement

Concerns have been intensified by Washington's move to suspend the major technology agreement, which was previously described as "a transformative pact" in the bilateral relationship. The US cited a failure to advance from the UK on lowering trade barriers as the reason for the pause.

In a separate development, concessions promised for British farmers as part of an earlier tariff deal have not been formally approved by the US, despite a looming January deadline. "It is our belief that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have expressed concerns that the government's deals with Washington are unstable and unpredictable. One minister reportedly said the series of agreements as "resting on shaky ground," while another described the situation as the "new normal" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, stated: "What is even more astonishing than Trump's temper tantrums is the UK government's naive belief that his administration is a trustworthy negotiator. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Officials have attempted to minimize the risk of the US backing out of the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been pushing for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that instability is inherent in dealing with the current US leadership. However, they contend that the UK has achieved real benefits for businesses, such as lower steel tariffs compared to other nations. "The fact we have 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

Nevertheless, delays have surfaced in carrying out the broader trade deal. Promised access for British beef have not materialized, and the assurance to "eliminate duties on UK metals" has is still pending, with tariffs remaining at 25%.

Moving forward, the two sides have agreed to resume talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.